Bio-Rad Laboratories, Inc. (BIO) Shares Bought by Comerica Bank
Comerica Bank boosted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 13.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,959 shares of the medical research company’s stock after buying an additional 2,073 shares during the period. Comerica Bank owned approximately 0.06% of Bio-Rad Laboratories worth $4,963,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of BIO. Boussard & Gavaudan Investment Management LLP purchased a new stake in Bio-Rad Laboratories in the 3rd quarter valued at about $202,000. World Asset Management Inc acquired a new position in Bio-Rad Laboratories in the 2nd quarter valued at about $213,000. Regentatlantic Capital LLC acquired a new position in Bio-Rad Laboratories in the 3rd quarter valued at about $222,000. We Are One Seven LLC acquired a new position in Bio-Rad Laboratories in the 3rd quarter valued at about $254,000. Finally, Atria Investments LLC acquired a new position in Bio-Rad Laboratories in the 3rd quarter valued at about $337,000. Hedge funds and other institutional investors own 63.87% of the company’s stock.
Several research firms have weighed in on BIO. Jefferies Financial Group lifted their target price on Bio-Rad Laboratories from $325.00 to $355.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Barclays dropped their target price on Bio-Rad Laboratories from $345.00 to $315.00 and set an “equal weight” rating for the company in a research report on Friday, November 2nd. Zacks Investment Research downgraded Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research report on Monday. Morgan Stanley began coverage on Bio-Rad Laboratories in a research report on Thursday, September 20th. They issued an “equal weight” rating and a $335.00 target price for the company. Finally, Goldman Sachs Group began coverage on Bio-Rad Laboratories in a research report on Wednesday, October 17th. They issued a “buy” rating and a $350.00 target price for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $338.43.
Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, November 1st. The medical research company reported $0.91 EPS for the quarter, missing the Zacks’ consensus estimate of $1.16 by ($0.25). Bio-Rad Laboratories had a return on equity of 3.72% and a net margin of 55.13%. The company had revenue of $545.10 million for the quarter, compared to analyst estimates of $541.23 million. During the same period in the prior year, the firm posted $0.91 earnings per share. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 5.47 earnings per share for the current fiscal year.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Article: What is the yield curve?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.